ArticleInfection and drug resistance2018
Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Clinical characteristics and outcomes of Candida tropicalis fungemia in patients with hematologic diseases: a single-center retrospective study in China (2018-2024).BMC infectious diseases · 2026Article
- Clinical and Molecular Epidemiological Characteristics of 26 Bloodstream Infection Cases Caused by Candida tropicalis.Mycopathologia · 2025Article
- Antifungal drug resistance in Candida glabrata: role of cellular signaling and gene regulatory networks.FEMS yeast research · 2025Review
- Research progress on the drug resistance mechanisms ofFrontiers in microbiology · 2025Review
- The prevalence, patterns, and antifungal drug resistance of bloodstream infection-causing fungi in Sichuan Province, China (2019-2023): a retrospective observational study using national monitoring data.Frontiers in microbiology · 2025Article
- Genomic epidemiology of human candidaemia isolates in a tertiary hospital.Microbial genomics · 2023Article
- The emerging threat antifungal-resistantFrontiers in fungal biology · 2022Review
- Continual Decline in Azole Susceptibility Rates inFrontiers in microbiology · 2021Article
- Article
- The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens.Journal of fungi (Basel, Switzerland) · 2020Review
- Breakthrough Bloodstream Infections Caused by Echinocandin-ResistantJournal of fungi (Basel, Switzerland) · 2020Article
- NovelEmerging microbes & infections · 2019Article
- Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum.Mycopathologia · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinocandin antifungal agents have become the first-line therapy for invasive candidiasis (IC) in many countries. Despite their increasing use, resistance to this class of drug is, overall, still uncommon. Here, we report two patients from the People's Republic of China with IC, one with infection caused by pan-echinocandin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.